Radius Health, Inc.

NasdaqGM:RDUS Stok Raporu

Piyasa değeri: US$480.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Radius Health Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

G. Martin

İcra Kurulu Başkanı

US$3.5m

Toplam tazminat

CEO maaş yüzdesi17.17%
CEO görev süresi2.3yrs
CEO sahipliğin/a
Yönetim ortalama görev süresiless than a year
Yönetim Kurulu ortalama görev süresi6.8yrs

Son yönetim güncellemeleri

Güncelleme yok

Recent updates

Seeking Alpha • Mar 14

Radius Recycling's Surge Justifies A Reevaluation

Summary Radius Recycling, Inc. shares surged after agreeing to a $30 per share buyout by Toyota Tsusho, offering a 115% premium over the closing price. Despite operational challenges and declining revenues, the buyout provides a significant 77.8% upside since my “buy” rating in June last year. Toyota Tsusho's acquisition reflects their strategic interest in metals recycling, but they assume all risks amid potential market recovery and volatility. Given the substantial premium and limited future upside, I recommend downgrading RDUS stock to a “hold” to align with broader market performance expectations. Read the full article on Seeking Alpha
Seeking Alpha • Feb 25

Radius Recycling Will Benefit From Steel Tariffs

Summary Radius Recycling's profitability is poised to improve due to rising domestic steel prices driven by tariffs, which will increase scrap steel prices and expand margins. Despite historical underperformance, the company's margins will benefit from higher scrap prices without significant cost increases, making it a speculative buy. Monitoring scrap steel prices before Radius's next earnings report could reveal an undervalued stock if the market hasn't yet recognized this linkage. Investing in Radius should be modest, as its viability heavily relies on the continuation of steel tariffs boosting scrap prices. Read the full article on Seeking Alpha
Seeking Alpha • Jul 16

Radius Recycling Stays In The Scrap Pile

Summary Radius Recycling experienced a significant decline in share price, hitting a 52-week low of $12.72. The company is implementing strategic changes to boost profits, including upgrades to non-ferrous scraping capabilities and cost reduction initiatives. Economic indicators such as durable goods orders, average vehicle age, and Chinese steel export production will impact Radius Recycling's business in the near future. Read the full article on Seeking Alpha
Seeking Alpha • Jun 03

Radius Recycling: An Attractive, But Volatile, Play On A Cleaner Future

Summary Radius Recycling, Inc. is a large recycler of ferrous and nonferrous metal, with operations in metals recycling, auto parts stores, and steel manufacturing. The company's financial performance has been volatile due to fluctuating steel prices, but its stock is trading at low multiples. Despite short-term challenges, the long-term potential of the recycling industry makes Radius Recycling a cheap business worth considering. Read the full article on Seeking Alpha
Seeking Alpha • Aug 11

Radius stock rises as elacestrant gets FDA priority review to treat breast cancer subtype

The U.S. Food and Drug Administration (FDA) granted priority review to Menarini's application seeking approval of elacestrant to treat patients with ER+/HER2- advanced or metastatic breast cancer. The FDA accepted the Italian pharmaceutical and diagnostic company's new drug application (NDA) and is expected to make a decision by Feb. 17, 2023. Under priority review, the FDA's goal is to take action within six months, compared to 10 months under standard review. The NDA was backed by data from a phase 3 trial called EMERALD, which was conducted by Radius Health (NASDAQ:RDUS).  Menarini had obtained global licensing rights for elacestrant from Radius in July 2020. Menarini noted that it had filed for approval of the drug in the EU in July 2022. Elacestrant had received the FDA's fast track designation in 2018. RDUS +5.56% to $10.64 premarket Aug. 11
Seeking Alpha • Feb 24

Reevaluating Radius Health

Radius Health, Inc. has lost over half its value since the transdermal patch version of its approved osteoporosis therapy (TYMLOS) flunked a Phase 3 trial in December 2021. Its other late-stage asset (elacestrant) just passed a Phase 3 study for breast cancer, but revenue from it will be muted since it divested its developmental and commercial rights to. Some recent small wins for subcutaneously injected TYMLOS, a soon-to-be-investigated CBD asset, and recent beneficial owner buying merited a deeper dive. A full investment analysis follows in the paragraphs below.
Analiz Makalesi • Feb 23

When Will Radius Health, Inc. (NASDAQ:RDUS) Become Profitable?

We feel now is a pretty good time to analyse Radius Health, Inc.'s ( NASDAQ:RDUS ) business as it appears the company...
Analiz Makalesi • Jan 01

How Much Did Radius Health's(NASDAQ:RDUS) Shareholders Earn From Share Price Movements Over The Last Five Years?

It is doubtless a positive to see that the Radius Health, Inc. ( NASDAQ:RDUS ) share price has gained some 58% in the...

CEO Tazminat Analizi

G. Martin'un ücretlendirmesi Radius Health'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2022n/an/a

-US$69m

Mar 31 2022n/an/a

-US$73m

Dec 31 2021US$3mUS$600k

-US$70m

Sep 30 2021n/an/a

-US$76m

Jun 30 2021n/an/a

-US$60m

Mar 31 2021n/an/a

-US$87m

Dec 31 2020US$12mUS$413k

-US$109m

Tazminat ve Piyasa: G. 'nin toplam tazminatı ($USD 3.49M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 2.51M ).

Tazminat ve Kazançlar: G. 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

G. Martin (63 yo)

2.3yrs
Görev süresi
US$3,493,881
Tazminat

Mr. G. Kelly Martin has been Executive Chairman of Wren Therapeutics Ltd. since 2018. Mr. Martin serves as the Chief Executive Officer, President and Director at Radius Health, Inc. since April 28, 2020.H...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
G. Martin
CEO, President & Director2.3yrsUS$3.49mVeri yok
Danielle Holtschlag
VP of Sales & Head of U.S. Sales Channelsless than a yearUS$741.78kVeri yok
Chhaya Shah
Senior VP & Chief Business Officer2.2yrsUS$1.22m0.27%
$ 1.3m
Stavros Manolagas
Founder & Member of the Scientific Advisory Boardno dataVeri yokVeri yok
John Potts
Founder & Member of the Scientific Advisory Boardno dataVeri yokVeri yok
Michael Rosenblatt
Founderno dataVeri yokVeri yok
John Katzenellenbogen
Founder & Member of the Scientific Advisory Boardno dataVeri yokVeri yok
Mark Conley
VP, CFOless than a yearVeri yokVeri yok
Peter Schwartzman
Head of Corporate Financeno dataVeri yokVeri yok
Ethan Holdaway
Head of Investor Relationsless than a yearVeri yokVeri yok
Kim Clarke
General Counselless than a yearVeri yokVeri yok
Rohan Lathia
Head of Corporate & Business Developmentless than a yearVeri yokVeri yok
0.8yrs
Ortalama Görev Süresi
61.5yo
Ortalama Yaş

Deneyimli Yönetim: RDUS 'un yönetim ekibi deneyimli olarak kabul edilmiyor ( 0.8 yıl), bu da yeni bir ekibin varlığını gösteriyor.

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
G. Martin
CEO, President & Director2.3yrsUS$3.49mVeri yok
Stavros Manolagas
Founder & Member of the Scientific Advisory Boardno dataVeri yokVeri yok
John Potts
Founder & Member of the Scientific Advisory Boardno dataVeri yokVeri yok
Michael Rosenblatt
Founderno dataVeri yokVeri yok
John Katzenellenbogen
Founder & Member of the Scientific Advisory Boardno dataVeri yokVeri yok
Jean-Pierre Garnier
Independent Director6.7yrsUS$544.81k0.045%
$ 215.1k
Sean Murphy
Independent Director2yrsUS$534.84k0.012%
$ 55.5k
Willard Dere
Independent Director7.8yrsUS$536.69k0.037%
$ 178.7k
Cecil Richard Lyttle
Chairman of Scientific Advisory Board10.5yrsUS$30.00kVeri yok
Owen Hughes
Independent Chairman9.3yrsUS$832.23k0.034%
$ 163.1k
Catherine Friedman
Independent Director7yrsUS$556.41k0.045%
$ 215.1k
Gary Hattersley
Member of Scientific Advisory Board3.8yrsUS$1.94mVeri yok
6.8yrs
Ortalama Görev Süresi
68.5yo
Ortalama Yaş

Deneyimli Yönetim Kurulu: RDUS 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.8 yıldır).

Şirket Analizi ve Finansal Veri Durumu

VeriSon Güncelleme (UTC saati)
Şirket Analizi2022/08/11 09:21
Gün Sonu Hisse Fiyatı2022/08/11 00:00
Kazançlar2022/06/30
Yıllık Kazançlar2021/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

PaketVeriZaman ÇerçevesiÖrnek ABD Kaynağı *
Şirket Finansalları10 yıl
  • Gelir tablosu
  • Nakit akış tablosu
  • Bilanço
Analist Konsensüs Tahminleri+3 yıl
  • Finansal tahminler
  • Analist fiyat hedefleri
Piyasa Fiyatları30 yıl
  • Hisse senedi fiyatları
  • Temettüler, Bölünmeler ve Eylemler
Sahiplik10 yıl
  • En büyük hissedarlar
  • İçeriden öğrenenlerin ticareti
Yönetim10 yıl
  • Liderlik ekibi
  • Yönetim Kurulu
Önemli Gelişmeler10 yıl
  • Şirket duyuruları

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

Radius Health, Inc. 12 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

AnalistKurum
Gregory HarrisonBofA Global Research
John NewmanCanaccord Genuity
Mara GoldsteinCantor Fitzgerald & Co.